Lopez H, Vilches V, Scarano S, Stepanik D, Smayevsky J, Lemme L, Cardeñosa O, Ambler J, Sucari A
Centro de Infectología, Pacheco de Melo 3068, Buenos Aires 1425, Argentina.
Int J Antimicrob Agents. 2001 Oct;18(4):379-82. doi: 10.1016/s0924-8579(01)00419-8.
The in vitro activity of moxifloxacin was compared with that of ciprofloxacin, levofloxacin, ofloxacin and trovafloxacin against 710 strains (180 Streptococcus pneumoniae, 180 Haemophilus influenzae, 160 Moraxella catarrhalis and 190 Streptococcus pyogenes) isolated from patients with community-acquired respiratory tract infections. MIC values for moxifloxacin, trovafloxacin were 0.25/0.25, 0.03/0.03, 0.06/0.03 and 0.125/0.0125 mg/l for S. pneumoniae, H. influenzae, M. catharralis and S. pyogenes. Based upon the MIC(90) values and the MIC distributions, moxifloxacin and trovafloxacin were the most active of the quinolones tested. They showed enhanced activity against Gram-positive organisms including penicillin non susceptible S. pneumoniae strains. Moxifloxacin was also highly active against ciprofloxacin-resistant S. pneumoniae strains.
将莫西沙星与环丙沙星、左氧氟沙星、氧氟沙星和曲伐沙星的体外活性进行比较,以检测其对710株从社区获得性呼吸道感染患者中分离出的菌株(180株肺炎链球菌、180株流感嗜血杆菌、160株卡他莫拉菌和190株化脓性链球菌)的抗菌活性。莫西沙星、曲伐沙星对肺炎链球菌、流感嗜血杆菌、卡他莫拉菌和化脓性链球菌的MIC值分别为0.25/0.25、0.03/0.03、0.06/0.03和0.125/0.0125mg/L。基于MIC(90)值和MIC分布,莫西沙星和曲伐沙星是所测试喹诺酮类药物中活性最强的。它们对革兰氏阳性菌包括青霉素不敏感的肺炎链球菌菌株显示出增强的活性。莫西沙星对耐环丙沙星的肺炎链球菌菌株也具有高活性。